Announcement

Collapse
No announcement yet.

Viruses . Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Viruses . Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)


    Viruses


    . 2020 Jun 10;12(6):E628.
    doi: 10.3390/v12060628.
    Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)


    Shuofeng Yuan 1 , Chris Chun-Yiu Chan 1 , Kenn Ka-Heng Chik 1 , Jessica Oi-Ling Tsang 1 , Ronghui Liang 1 , Jianli Cao 1 , Kaiming Tang 1 , Jian-Piao Cai 1 , Zi-Wei Ye 1 , Feifei Yin 2 , Kelvin Kai-Wang To 1 , Hin Chu 1 , Dong-Yan Jin 3 , Ivan Fan-Ngai **** 4 , Kwok-Yung Yuen 1 2 , Jasper Fuk-Woo Chan 1 2



    AffiliationsFree article

    Abstract

    The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) signals an urgent need for an expansion in treatment options. In this study, we investigated the anti-SARS-CoV-2 activities of 22 antiviral agents with known broad-spectrum antiviral activities against coronaviruses and/or other viruses. They were first evaluated in our primary screening in VeroE6 cells and then the most potent anti-SARS-CoV-2 antiviral agents were further evaluated using viral antigen expression, viral load reduction, and plaque reduction assays. In addition to remdesivir, lopinavir, and chloroquine, our primary screening additionally identified types I and II recombinant interferons, 25-hydroxycholesterol, and AM580 as the most potent anti-SARS-CoV-2 agents among the 22 antiviral agents. Betaferon (interferon-β1b) exhibited the most potent anti-SARS-CoV-2 activity in viral antigen expression, viral load reduction, and plaque reduction assays among the recombinant interferons. The lipogenesis modulators 25-hydroxycholesterol and AM580 exhibited EC50 at low micromolar levels and selectivity indices of >10.0. Combinational use of these host-based antiviral agents with virus-based antivirals to target different processes of the SARS-CoV-2 replication cycle should be evaluated in animal models and/or clinical trials.

    Keywords: 25-hydroxycholesterol; AM580; COVID-19; coronavirus; interferon; treatment.

Working...
X